Barker F G, Prados M D, Chang S M, Davis R L, Gutin P H, Lamborn K R, Larson D A, McDermott M W, Sneed P K, Wilson C B
Neuro-Oncology Service, School of Medicine, University of California, San Francisco, CA 94143, USA.
Int J Radiat Oncol Biol Phys. 1996 Mar 1;34(4):803-8. doi: 10.1016/0360-3016(95)02027-6.
Various measures of the rate of tumor cell proliferation have been found to predict survival in patients with intracerebral gliomas. We correlated the bromodeoxyuridine labeling index (BrdUrd LI) with the response to radiation therapy, survival, and known prognostic factors in a series of patients with glioblastoma multiforme (GM) to test its utility as a prognostic factor.
The BrdUrd LI was determined in 200 newly diagnosed intracranial GMs. Age and sex were known for all patients. The response to radiation therapy was determined in 116 patients by comparing neuroimaging studies obtained before and after external beam radiation therapy. Survival was analyzed in 64 patients who were treated according to two consecutive prospective clinical protocols.
The median BrdUrd LI was 6.5% (mean, 7.2%; range, 1.1-25.4%). The BrdUrd LI did not correlate significantly with age, sex, radiation response, or survival. Age and Karnofsky performance score were independent prognostic factors in our cohort.
The proliferative rate as measured by BrdUrd LI was not a prognostic factor in our GM cohort. The BrdUrd LI did not correlate significantly with known prognostic factors in GM. There was no significant relationship between BrdUrd LI and radiation response.
已发现多种肿瘤细胞增殖速率的测量方法可预测脑内胶质瘤患者的生存情况。我们将溴脱氧尿苷标记指数（BrdUrd LI）与一系列多形性胶质母细胞瘤（GM）患者的放射治疗反应、生存情况及已知预后因素进行关联分析，以检验其作为预后因素的效用。
测定了200例新诊断的颅内GM患者的BrdUrd LI。所有患者的年龄和性别均已知。通过比较外照射放疗前后获得的神经影像学研究结果，确定了116例患者的放射治疗反应。根据两个连续的前瞻性临床方案对64例接受治疗的患者进行了生存分析。
BrdUrd LI的中位数为6.5%（平均值为7.2%；范围为1.1 - 25.4%）。BrdUrd LI与年龄、性别、放射治疗反应或生存情况均无显著相关性。年龄和卡诺夫斯基功能状态评分是我们队列中的独立预后因素。
在我们的GM队列中，以BrdUrd LI测量的增殖速率不是一个预后因素。BrdUrd LI与GM中已知的预后因素无显著相关性。BrdUrd LI与放射治疗反应之间无显著关系。
